We are live on ! Find out more
LEXX icon

Lexaria Bioscience
LEXX

16 hedge funds and large institutions have $1.67M invested in Lexaria Bioscience in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.16% more ownership

Funds ownership: 11.56% → 11.72% (+0.16%)

0% more funds holding

Funds holding: 16 → 16 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 5

1% less capital invested

Capital invested by funds: $1.68M → $1.67M (-$8.44K)

Holders
16
Holders Change
–
Holders Change %
0%
% of All Funds
0.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
5
Reduced
5
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$62.3K
2
1832 Asset Management
1832 Asset Management
Ontario, Canada
+$6.43K
3
TRCT
Tower Research Capital (TRC)
New York
+$3.34K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$395
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$10

Top Sellers

Rank Fund Capital Flow
1
Two Sigma Investments
Two Sigma Investments
New York
-$32K
2
Citadel Advisors
Citadel Advisors
Florida
-$14.8K
3
UBS Group
UBS Group
Switzerland
-$1.92K
4
Renaissance Technologies
Renaissance Technologies
New York
-$957
5
CC
Centiva Capital
New York
-$479
Name Holding Trade Value Shares
Change 		Change in
Stake
ICM
1
Invenomic Capital Management
Massachusetts
$1.16M – – –
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
$162K +$62.3K +26,012 +65%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$119K -$395 -165 -0.3%
Vanguard Group
4
Vanguard Group
Pennsylvania
$82K +$395 +165 +0.5%
Citadel Advisors
5
Citadel Advisors
Florida
$45.8K -$14.8K -6,200 -25%
CC
6
Centiva Capital
New York
$32K -$479 -200 -2%
Renaissance Technologies
7
Renaissance Technologies
New York
$28K -$957 -400 -3%
UBS Group
8
UBS Group
Switzerland
$13.8K -$1.92K -802 -13%
TRCT
9
Tower Research Capital (TRC)
New York
$12K +$3.34K +1,396 +38%
1832 Asset Management
10
1832 Asset Management
Ontario, Canada
$6.61K +$6.43K +2,686 New
Osaic Holdings
11
Osaic Holdings
Arizona
$5K – – –
Wells Fargo
12
Wells Fargo
California
$2.55K +$2 +1 +0.1%
Royal Bank of Canada
13
Royal Bank of Canada
Ontario, Canada
$1K – – –
APC
14
Aspire Private Capital
North Carolina
$984 – – –
Dimensional Fund Advisors
15
Dimensional Fund Advisors
Texas
$37 +$10 +4 +0%
GCM
16
Gables Capital Management
Florida
$32 – – –
Two Sigma Investments
17
Two Sigma Investments
New York
– -$32K -13,063 Closed

LEXX Hedge Fund Activity: Q4 2022 in Review

16 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience (LEXX) for Q4 2022, worth a combined $1.67M — down 0.5% from $1.68M a quarter earlier.

Fund positioning in LEXX was balanced in Q4 2022: 1 fund opened new positions, 1 closed out, 5 added to existing stakes and 5 trimmed.

The largest buyer was Susquehanna International Group, adding an estimated $62.3K. The largest seller was Two Sigma Investments, exiting entirely with an estimated $32K sold.

  • 16 institutional investors held Lexaria Bioscience (LEXX) as of Q4 2022, unchanged from Q3 2022.
  • Funds reported $1.67M of Lexaria Bioscience stock for Q4 2022, down 0.5% quarter-over-quarter.
  • 1 fund opened new Lexaria Bioscience positions in Q4 2022 and 1 closed out, a net change of 0 holders.
  • The largest Lexaria Bioscience buyer in Q4 2022 was Susquehanna International Group, an estimated $62.3K added.
  • The largest Lexaria Bioscience seller in Q4 2022 was Two Sigma Investments, an estimated $32K sold.

Based on aggregated 13F filings for Q4 2022.